Learn about the causes of age-related hearing loss and discover effective strategies to manage presbycusis. Early ...

Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

The most common form of hereditary deafness in humans is caused by mutations in the GJB2 gene, which encodes the gap junction protein connexin 26. That regulates the transport of potassium and ...

Ten children who received DB-OTO for profound genetic hearing loss due to variants of the otoferlin gene showed notable ...

After NIH-funded studies linked untreated hearing loss to health issues such as dementia, Hopkins professor Frank Lin ...

A low-cost otoacoustic emission probe and smartphone app performed as well as commercially available devices for hearing loss ...

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...

Hearing loss comes in many forms, but one of the most common forms is presbycusis — gradual hearing loss that develops with ...

Sensorion receives DMC recommendation to continue the Audiogene phase 1/2 trial of SENS-501: Montpellier, France Monday, February 24, 2025, 18:00 Hrs [IST] Sensorion, a pioneering ...

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearingSpeech and development ...